caa a22 4500 47581908X CHVBK 20180406123817.0 cr unu---uuuuu 170329e20000501xx s 000 0 eng 10.1007/s002280050732 doi (NATIONALLICENCE)springer-10.1007/s002280050732 Absorption of effervescent paracetamol tablets relative to ordinary paracetamol tablets in healthy volunteers [Elektronische Daten] [T. Rygnestad, K. Zahlsen, F. A. Samdal] Objectives: The aim of this study was to compare the rate of absorption between ordinary paracetamol tablets and effervescent paracetamol tablets. Methods: Twenty healthy volunteers participated in an open randomised crossover study and were given a 1000-mg dose of either ordinary paracetamol tablets (2 × 500 mg Panodil tablets, SmithKline Beecham) or effervescent paracetamol tablets (2 × 500 mg Pinex Brusetablett, Alpharma AS) with a 3-week washout period in between. Blood samples were collected for 3 h. Maximum serum concentration (Cmax) and the time to maximum serum concentration (tmax) were recorded and the area under the concentration versus time curve (AUC) was calculated. Results: The mean tmax was significantly shorter when paracetamol effervescent tablets were taken (27 min) rather than ordinary paracetamol tablets (45 min) (P=0.004). There was no significant difference between the mean Cmax of 143 μmol/l with effervescent tablets and that of 131 μmol/l with ordinary tablets. The mean AUC0-3 h was significantly higher with paracetamol effervescent tablets (223.8 μmol · h · l−1) than with ordinary tablets (198.2 μmol · h · l−1; P=0.003). After 15 min, 17 (85%) subjects in the effervescent group had a serum concentration of 70 μmol/l (lower therapeutic serum concentration) or higher relative to only 2 (10%) subjects in the ordinary tablet group (P=0.001). Conclusion: Paracetamol effervescent tablets are absorbed significantly faster than ordinary paracetamol. Thus, effervescent tablets might offer significantly faster pain relief when paracetamol is used. Springer-Verlag Berlin Heidelberg, 2000 Key words Paracetamol tablets nationallicence Effervescent nationallicence tmax nationallicence Cmax nationallicence AUC nationallicence Rygnestad T. Section of Clinical Pharmacology, Department of Clinical Pharmacology and Pharmacy, The Regional and University Hospital in Trondheim, N-7006 Trondheim, Norway e-mail: tarjei.rygnestad@relis.rit.no Tel.: +47-73-550160, +47-73-550165; Fax: +47-73-550166, NO aut Zahlsen K. Section of Clinical Pharmacology, Department of Clinical Pharmacology and Pharmacy, The Regional and University Hospital in Trondheim, N-7006 Trondheim, Norway e-mail: tarjei.rygnestad@relis.rit.no Tel.: +47-73-550160, +47-73-550165; Fax: +47-73-550166, NO aut Samdal F. A. Klinikk Stokkan, Fjordgata 68, N-7010 Trondheim, Norway, NO aut https://doi.org/10.1007/s002280050732 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050732 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Rygnestad T. Section of Clinical Pharmacology, Department of Clinical Pharmacology and Pharmacy, The Regional and University Hospital in Trondheim, N-7006 Trondheim, Norway e-mail: tarjei.rygnestad@relis.rit.no Tel.: +47-73-550160, +47-73-550165; Fax: +47-73-550166, NO aut NATIONALLICENCE 700 1- Zahlsen K. Section of Clinical Pharmacology, Department of Clinical Pharmacology and Pharmacy, The Regional and University Hospital in Trondheim, N-7006 Trondheim, Norway e-mail: tarjei.rygnestad@relis.rit.no Tel.: +47-73-550160, +47-73-550165; Fax: +47-73-550166, NO aut NATIONALLICENCE 700 1- Samdal F. A. Klinikk Stokkan, Fjordgata 68, N-7010 Trondheim, Norway, NO aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer